Livongo ups IPO range, eyes $2.2B valuation

Livongo Health, the developer of a platform that helps patients manage chronic conditions like diabetes and hypertension, has increased its expected IPO price range to $24 to $26 per share after initially estimating a range of $20 to $23. A midpoint pricing would now raise $267.5 million and value the Bay Area company at more than $2.2 billion. Livongo plans to list on the NASDAQ under the symbol LVGO; its investors include General Catalyst (25.4% pre-IPO stake) and Kinnevik (12%).

Lead Underwriters

Goldman Sachs, JP Morgan Securities, Morgan Stanley

View details

News & Analysis

Related content